Printer Friendly

Orthocell appoints Surgical Specialties as exclusive distributor in Australia and New Zealand.

M2 PHARMA-October 11, 2017-Orthocell appoints Surgical Specialties as exclusive distributor in Australia and New Zealand


Orthocell Ltd (ASX: OCC) has appointed Surgical Specialties Pty Ltd as its exclusive distributor in Australia and New Zealand, the company announced on Wednesday.

As a result of the decision, Surgical Specialties will exclusively distribute the company's therapies for tendon regeneration (Ortho-ATI) and cartilage regeneration (Ortho-ACI).

Surgical Specialties is an independent distributor of innovative medical devices to the Australian and New Zealand medical community. With sales offices throughout Australia and New Zealand, it has established relationships with leading orthopaedic surgeons and sports physicians.

The company's responsibilities will include targeted promotion activities and initiating sales, as well as helping to expand the network of referring doctors and physicians.

The agreement is set to run for five years, allowing Orthocell to focus on the development of its novel regenerative medicine products and drive national and international regulatory approvals for its technologies.

((Comments on this story may be sent to

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:8AUST
Date:Oct 11, 2017
Previous Article:Generon receives SPA from US FDA for global Phase III trial of F-627.
Next Article:Evotec and Celgene reach first milestone generating revenues of USD5m to Evotec.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters